Survodutide for non-alcoholic fatty liver disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Mar 2024: Trial registered, NCT06309992
  2. 2 Apr 2024: Trial started, NCT06309992

The trials

NCT06309992: A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)

State
Completed
Phase
Phase 3
People
218 taking part
Started
2 Apr 2024
Primary completion
9 Oct 2025
Arms
Treatment arm
Results
None posted
Papers
doi:10.1111/apt.70020
  1. 13 Mar 2024: Trial registered
  2. 2 Apr 2024: Trial started
  3. 2 Dec 2025: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as BI 456906, Survodutide formulation A, Survodutide formulation B2.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.